RACTHERA Co., Ltd. is a joint venture established
by Sumitomo Chemical Co., Ltd. and Sumitomo Pharma Co., Ltd.
with the mission of advancing research and development in regenerative and cellular medicine.

By fully leveraging Sumitomo Pharma’s robust pharmaceutical-business
foundation and integrating it with Sumitomo Chemical’s expertise in industrialization,
analytical technologies, and quality control know-how,

RACTHERA strives to accelerate research,
development, and commercialization.

Furthermore, through close collaborating with S-RACMO Co., Ltd.,
a group company specialized in cell production and manufacturing technologies,
we aim to further strengthen our position in the highly promising field.

As a “Front Runner” in regenerative and cellular medicine,
RACTHERA is committed to delivering new value that can only be achieved through regenerative medicine.

Pharmaceuticals have advanced and evolved throughout human history. Liberating countless individuals from the burden of illness and injury, and enabling them to regain healthy lives. However, conventional pharmaceuticals face limitations ; namely, once a physiological function is lost, it becomes difficult to restore it therefore leaving many diseases without effective treatments options.

Regenerative and cellular medicine will provide a fundamentally different approach from conventional pharmaceuticals, unlocking tremendous potential to deliver innovative treatments for diseases that were previously considered untreatable.

RACTHERA Co., Ltd. is dedicated to advancing research and development in regenerative and cellular medicine to realize this potential. We aspire to harness the groundbreaking discovery of iPS cells, a shining milestone in the history of science-and apply it, to regenerative medicine to, save countless patients. While many challenges lie ahead, we remain committed to pushing and breaking the boundaries and embracing new frontiers to deliver the future, next generation of medical treatments to those in need.